Collaboration Will Seek to Identify Unique microRNA Signatures That Will
Predict Risk of Recurrence in Lung Cancer Patients The Project Will Leverage Rosetta Genomics' Proprietary microRNA Extraction and Quantification Technologies, and M. D. Anderson's Extensive Know-How
and Experience in Lung Cancer Research Test Will be Designed to Assist in Distinguishing Patients With High Risk of Recurrence, who may Benefit From Adjuvant or Targeted Therapies, From
Those With Low Risk
REHOVOT, Israel and JERSEY CITY, New Jersey, June 6 /PRNewswire-FirstCall/ -- Rosetta Genomics, Ltd. (NASDQ: ROSG), a leader in the development of microRNA-based diagnostic and therapeutic products, announced today a research collaboration with The University of Texas M. D. Anderson Cancer Center and the Kleberg Center for Molecular Markers to develop a microRNA- based diagnostic test to predict risk of disease recurrence in lung cancer patients who have undergone curative resection.
Current treatment for lung cancer includes surgical resection which may be followed by adjuvant therapy. While patients with high risk of recurrence may benefit from adjuvant therapy, those with low risk of recurrence may be exposed to unnecessary toxicities. The goal of this collaboration is to develop a test that will enable physicians to distinguish between patients with high and low risk of recurrence to optimize treatment regimens.
"The potential diagnostic applications of microRNA biomarkers are broad and diverse," noted Amir Avniel, president and CEO of Rosetta Genomics. "We are very pleased to be collaborating with M. (space) D. Anderson, one of the world's leading cancer research centers, on this important project in lung cancer. We believe that the experience we have in working with microRNA biomarkers, combined with M. (space) D. Anderson's extensive experience in lung cancer research, makes this a strong collaboration which may have a significant impact on the way lung cancer patients are diagnosed and treated."
Lung cancer is the leading cause of cancer death among both men and women worldwide and in the United States. In 2008 alone, there will be about 215,020 new cases of lung cancer in the United States, and approximately 160,000 people will die of the disease(1).
"We are quickly learning about the benefits of better diagnostics in optimizing treatment administration," said Ignacio I. Wistuba, M.D., associate professor, Department of Pathology at
M. D. Anderson Cancer Center. "Currently, the lack of sensitive diagnostic tools means lung cancer patients, who have undergone a resection, may be administered aggressive chemotherapy despite the fact that they are at low risk of the cancer recurring. By leveraging microRNAs' unique sensitivity as biomarkers, we have an opportunity to develop a novel test that will assist clinicians and patients to better manage this type of cancer."
"The use of miRNA with existing genomic and proteomic information will help us achieve the goal of personalization of the treatment," said Gordon Mills, co-director of the Kleberg Center for Molecular Markers, at M. D. Anderson Cancer Center.
"This is one of the many collaborations with industry leaders that the Kleberg Center is building to bring novel technologies to achieve our mission of affecting treatment changes," said Rahul Mitra, associate director of the Kleberg Center.
MicroRNAs (miRNAs) are recently discovered, naturally occurring, small RNAs that act as master regulators and have the potential to form the basis for a new class of diagnostics and therapeutics. Since many diseases are caused by the abnormal activity of proteins, the ability to selectively regulate protein activity through microRNAs could provide the means to treat a wide range of human diseases. In addition, microRNAs have been shown to have different expression in various pathological conditions. As a result, these differences may provide for a novel diagnostic strategy for many diseases.
About Rosetta Genomics
Rosetta Genomics (Nasdaq: ROSG) is a leader in the field of microRNAs. Founded in 2000, the company's integrative research platform combining bioinformatics and state-of-the-art laboratory processes has led to the discovery of hundreds of biologically validated novel human microRNAs. Building on its strong IP position and proprietary platform technologies, Rosetta Genomics is working on the application of these technologies in the development of a full range of microRNA-based diagnostic and therapeutic tools, focusing primarily on cancer and various women's health indications. The company expects that the first microRNA diagnostic tests applying its technology will be launched by licensed clinical laboratories in the United States in 2008.
Forward-Looking Statement Disclaimer
Various statements in this release concerning Rosetta's future
expectations, plans and prospects, including without limitation, statements
relating to the role of microRNAs in human physiology and disease, the
potential of microRNAs in the diagnosis and treatment of disease and the
Company's ability to successfully develop lung cancer diagnostic tests,
specifically, through identifying unique microRNA signatures that may
predict risk of recurrence in stage I and II Non Small Cell Lung Cancer
(NSCLC) patients, constitute forward-looking statements for the purposes of
the safe harbor provisions under The Private Securities Litigation Reform
Act of 1995. Actual results may differ materially from those indicated by
these forward-looking statements as a result of various important factors,
including risks related to: Rosetta's approach to discover and develop
novel diagnostics and therapeutic tools, which is unproven and may never
lead to marketable products or services; Rosetta's ability to fund and the
results of further pre-clinical and clinical trials; Rosetta's ability to
obtain, maintain and protect the intellectual property utilized by
Rosetta's products; Rosetta's ability to enforce its patents against
infringers and to defend its patent portfolio against challenges from third
parties; Rosetta's ability to obtain additional funding to support its
business activities; Rosetta's dependence on third parties for development,
manufacture, marketing, sales, and distribution of products; Rosetta's
ability to successfully develop its candidate tools, products and services,
all of which are in early stages of development; Rosetta's ability to
obtain regulatory clearances or approvals that may be required for its
products and services; the ability to obtain coverage and adequate payment
from health insurers for the products and services comprising Rosetta's
technology; competition from others using technology similar to Rosetta's
and others developing products for similar uses; Rosetta's dependence on
collaborators; and Rosetta's short operating history; as well as those
risks more fully discussed in the "Risk Factors" section of Rosetta's
Annual Report on Form 20-F for the year ended December 31, 2006 as filed
with the Securities and Exchange Commission. In addition, any
forward-looking statements represent Rosetta's views only as of the date of
this release and should not be relied upon as representing its views as of
any subsequent date. Rosetta does not assume any obligation to update any
forward-looking statements unless required by law.
(1) American Cancer Society
|SOURCE Rosetta Genomics Ltd|
Copyright©2008 PR Newswire.
All rights reserved